Gilead Sciences (GS-6637) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
Gilead Sciences (GS-6637) General Information
Description
Phase-2 ready compound utilizing a novel pathway for the treatment of addiction. The compound is a inhibitor that modifies dopaminergic tone by preventing pathophysiologic dopamine surges and associated craving without changes to basal dopamine.
Contact Information
Corporate Office
- 333 Lakeside Drive
- Foster City, CA 94404
- United States
Corporate Office
- 333 Lakeside Drive
- Foster City, CA 94404
- United States
Gilead Sciences (GS-6637) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Gilead Sciences (GS-6637) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Gilead Sciences (GS-6637) FAQs
-
Where is Gilead Sciences (GS-6637) headquartered?
Gilead Sciences (GS-6637) is headquartered in Foster City, CA.
-
What industry is Gilead Sciences (GS-6637) in?
Gilead Sciences (GS-6637)’s primary industry is Buildings and Property.
-
Is Gilead Sciences (GS-6637) a private or public company?
Gilead Sciences (GS-6637) is a Private company.
-
What is Gilead Sciences (GS-6637)’s current revenue?
The current revenue for Gilead Sciences (GS-6637) is .
-
Who are Gilead Sciences (GS-6637)’s investors?
Gilead has invested in Gilead Sciences (GS-6637).
-
When was Gilead Sciences (GS-6637) acquired?
Gilead Sciences (GS-6637) was acquired on 16-Feb-2017.
-
Who acquired Gilead Sciences (GS-6637)?
Gilead Sciences (GS-6637) was acquired by Amygdala Neurosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process